Reem Karmali, MD, Feinberg School of Medicine, Northwestern University, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy on the treatment of patients with diffuse large B-cell lymphoma (DLBCL).

Patients who are refractory to chemotherapy now have CAR T-cell therapy as an option, according to Karmali. The SCHOLAR-1 study investigated the outcomes of patients with refractory DLBCL, which showed a median overall survival of 6 months. The addition of CAR T-cell therapy has benefitted this patient population, says Karmali.

Videos

Dr. Karmali on the Impact of CAR T-Cell Therapy in DLBCL

Reem Karmali, MD, Feinberg School of Medicine, Northwestern University, discusses the future of chimeric antigen receptor (CAR) T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

As cellular immunotherapy takes the forefront, CAR T-cell therapy is an encouraging modality of therapy, says Karmali. However, there are going to be challenges, such as toxicity management and how to incorporate CAR T-cell therapy into existing modalities of therapy.

Thus far, Karmali is optimistic about the CAR T-cell therapy results and believes it will drastically impact DLBCL.

Dr. Karmali on the Future of CAR T-Cell Therapy in DLBCL

Reem Karmali, MD, assistant professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses the toxicities associated with the use of chimeric antigen receptor (CAR) T-cell therapies.

There are 2 main toxicities that experts are worried about, says Karmali—cytokine release syndrome and neurotoxicity. It is not yet clear what the mechanism is for neurotoxicity.

Karmali says that the patients being selected should have relatively preserved organ function so that they can withstand these toxicities.

Dr. Karmali Discusses Toxicites Associated With CAR T-Cell Therapies

Reem Karmali, MD, assistant professor of medicine (hematology and oncology, Feinberg School of Medicine, Northwestern University, discusses the FDA approval of axicabtagene ciloleucel (Yescarta; KTE-C19; axi-cel) for the treatment of patients with non-Hodgkin lymphoma.

Reem Karmali, MD, assistant professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses the FDA approval of axicabtagene ciloleucel (KTE-C19; axi-cel) for the treatment of patients with non-Hodgkin lymphoma.

Reem Karmali, MD

Articles

Dr. Karmali on the Impact of CAR T-Cell Therapy in DLBCL

Dr. Karmali on the Future of CAR T-Cell Therapy in DLBCL

Dr. Karmali Discusses Toxicites Associated With CAR T-Cell Therapies

Dr. Karmali on FDA Approval of KTE-C19 in Non-Hodgkin Lymphoma